-DOCSTART- -X- O
OBJECTIVE -X- _ O
: -X- _ O
To -X- _ O
evaluate -X- _ O
the -X- _ O
efficacy -X- _ O
and -X- _ O
tolerability -X- _ O
of -X- _ O
sorafenib -X- _ B-Intervention
combined -X- _ I-Intervention
with -X- _ I-Intervention
cryoablation -X- _ I-Intervention
in -X- _ O
treating -X- _ O
unresectable -X- _ B-Patient
hepatocellular -X- _ I-Patient
carcinoma -X- _ I-Patient
( -X- _ I-Patient
HCC -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
METHODS -X- _ O
: -X- _ O
Patients -X- _ B-Patient
with -X- _ I-Patient
unresectable -X- _ I-Patient
advanced -X- _ I-Patient
HCC -X- _ I-Patient
received -X- _ B-Intervention
cryoablation -X- _ I-Intervention
and -X- _ I-Intervention
sorafenib -X- _ I-Intervention
at -X- _ I-Intervention
a -X- _ I-Intervention
dose -X- _ I-Intervention
of -X- _ I-Intervention
400 -X- _ I-Intervention
mg -X- _ I-Intervention
twice -X- _ I-Intervention
daily -X- _ I-Intervention
in -X- _ I-Intervention
4-week -X- _ I-Intervention
cycles -X- _ I-Intervention
on -X- _ I-Intervention
the -X- _ I-Intervention
same -X- _ I-Intervention
day -X- _ I-Intervention
of -X- _ I-Intervention
the -X- _ I-Intervention
cryoablation. -X- _ I-Intervention
Tumor -X- _ O
response -X- _ O
, -X- _ O
median -X- _ O
overall -X- _ O
survival -X- _ O
and -X- _ O
the -X- _ O
median -X- _ O
time -X- _ O
to -X- _ O
radiological -X- _ O
progression -X- _ O
were -X- _ O
calculated -X- _ O
and -X- _ O
the -X- _ O
toxicity -X- _ O
was -X- _ O
evaluated. -X- _ O
RESULTS -X- _ O
: -X- _ O
Seventy-eight -X- _ B-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
unresectable -X- _ I-Patient
HCC -X- _ I-Patient
were -X- _ O
involved -X- _ O
in -X- _ O
this -X- _ O
study. -X- _ O
The -X- _ O
median -X- _ O
age -X- _ O
was -X- _ O
52 -X- _ O
years -X- _ O
( -X- _ O
range -X- _ O
, -X- _ O
22-81 -X- _ O
years -X- _ O
) -X- _ O
. -X- _ O
The -X- _ B-Outcome
Eastern -X- _ I-Outcome
Cooperative -X- _ I-Outcome
Oncology -X- _ I-Outcome
Group -X- _ I-Outcome
( -X- _ I-Outcome
ECOG -X- _ I-Outcome
) -X- _ I-Outcome
performance -X- _ I-Outcome
status -X- _ I-Outcome
scores -X- _ I-Outcome
were -X- _ I-Outcome
0 -X- _ I-Outcome
( -X- _ I-Outcome
39.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
1 -X- _ I-Outcome
( -X- _ I-Outcome
55.1 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
2 -X- _ I-Outcome
( -X- _ I-Outcome
5.1 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Nine -X- _ I-Outcome
( -X- _ I-Outcome
11.5 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
patients -X- _ I-Outcome
were -X- _ I-Outcome
at -X- _ I-Outcome
Barcelona -X- _ I-Outcome
clinic -X- _ I-Outcome
liver -X- _ I-Outcome
cancer -X- _ I-Outcome
( -X- _ I-Outcome
BCLC -X- _ I-Outcome
) -X- _ I-Outcome
stage -X- _ I-Outcome
A -X- _ I-Outcome
, -X- _ I-Outcome
twenty-four -X- _ I-Outcome
( -X- _ I-Outcome
30.8 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
patients -X- _ I-Outcome
were -X- _ I-Outcome
at -X- _ I-Outcome
stage -X- _ I-Outcome
B -X- _ I-Outcome
and -X- _ I-Outcome
45 -X- _ I-Outcome
( -X- _ I-Outcome
57.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
patients -X- _ I-Outcome
were -X- _ I-Outcome
at -X- _ I-Outcome
stage -X- _ I-Outcome
C. -X- _ I-Outcome
Five -X- _ I-Outcome
( -X- _ I-Outcome
6.4 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
achieved -X- _ I-Outcome
partial -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
34 -X- _ I-Outcome
( -X- _ I-Outcome
43.6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
achieved -X- _ I-Outcome
stable -X- _ I-Outcome
disease. -X- _ I-Outcome
The -X- _ I-Outcome
median -X- _ I-Outcome
time -X- _ I-Outcome
to -X- _ I-Outcome
progression -X- _ I-Outcome
( -X- _ I-Outcome
TTP -X- _ I-Outcome
) -X- _ I-Outcome
for -X- _ I-Outcome
all -X- _ I-Outcome
enrolled -X- _ I-Outcome
patients -X- _ I-Outcome
was -X- _ I-Outcome
6.6 -X- _ I-Outcome
months -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
median -X- _ I-Outcome
overall -X- _ I-Outcome
survival -X- _ I-Outcome
( -X- _ I-Outcome
OS -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
12.2 -X- _ I-Outcome
months. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
Cryoablation -X- _ B-Outcome
combined -X- _ I-Outcome
with -X- _ I-Outcome
sorafenib -X- _ I-Outcome
demonstrates -X- _ I-Outcome
good -X- _ I-Outcome
efficacy -X- _ I-Outcome
and -X- _ I-Outcome
acceptable -X- _ I-Outcome
tolerability -X- _ I-Outcome
in -X- _ I-Outcome
treating -X- _ I-Outcome
unresectable -X- _ I-Outcome
advanced -X- _ I-Outcome
HCC -X- _ I-Outcome
patients -X- _ I-Outcome
. -X- _ O

